Experienced in Paget's Disease of Bone

Dr. Rohit Jain

Endocrinology
Gw Endocrinology-West End: 2300 M Street
2300 M St NW # 9, 
Washington, DC 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth

Experienced in Paget's Disease of Bone
Gw Endocrinology-West End: 2300 M Street
2300 M St NW # 9, 
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rohit Jain is an Endocrinologist in Washington, Washington, D.c.. Dr. Jain is rated as an Experienced provider by MediFind in the treatment of Paget's Disease of Bone. His top areas of expertise are Muscle Invasive Bladder Cancer, Hypercalcemia, Milk-Alkali Syndrome, Penectomy, and Endoscopy.

His clinical research consists of co-authoring 313 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Endocrinology
Licenses
Internal Medicine in MD
Hospital Affiliations
George Washington Univ Hospital
Suburban Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Gw Endocrinology-West End: 2300 M Street
2300 M St NW # 9, Washington, DC 20037
Call: 202-741-3422

Additional Areas of Focus

Dr. Jain has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Hypoparathyroidism
Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


11 Clinical Trials

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Recruiting
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
Phase Ib Trial of Erdafitinib Combined With Enfortumab Vedotin Following Prior Therapies for Metastatic Urothelial Carcinoma With FGFR2/3 Genetic Alterations.
Phase Ib Trial of Erdafitinib Combined With Enfortumab Vedotin Following Prior Therapies for Metastatic Urothelial Carcinoma With FGFR2/3 Genetic Alterations.
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug
Study Drugs: Enfortumab Vedotin, Erdafitinib
Study Phase: Phase 1
Phase I/II Study of Ipilimumab Plus Nivolumab (IPI-NIVO) Combined With Sacituzumab Govitecan (SG)as First-line Treatment for Cisplatin-ineligible Metastatic Urothelial Carcinoma
Phase I/II Study of Ipilimumab Plus Nivolumab (IPI-NIVO) Combined With Sacituzumab Govitecan (SG)as First-line Treatment for Cisplatin-ineligible Metastatic Urothelial Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab, Sacituzumab govitecan
Study Phase: Phase 1/Phase 2
A Phase 1 Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With Muscle Invasive Bladder Cancer (MIBC)
A Phase 1 Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With Muscle Invasive Bladder Cancer (MIBC)
Enrollment Status: Active_not_recruiting
Publish Date: December 09, 2025
Intervention Type: Drug
Study Drugs: CG0070, Nivolumab
Study Phase: Phase 1
A Pilot Study of Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
A Pilot Study of Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drug: Abiraterone Acetate
Study Phase: Early Phase 1
A Window-of-opportunity Trial of Abemaciclib Followed by Radical Cystectomy in Patients With Platinum-ineligible Urothelial Carcinoma to Evaluate CDK4/6-dependent Phosphorylation of Pocket Proteins and Clonal Evolution Dynamics
A Window-of-opportunity Trial of Abemaciclib Followed by Radical Cystectomy in Patients With Platinum-ineligible Urothelial Carcinoma to Evaluate CDK4/6-dependent Phosphorylation of Pocket Proteins and Clonal Evolution Dynamics
Enrollment Status: Active_not_recruiting
Publish Date: November 18, 2025
Intervention Type: Drug
Study Drug: Abemaciclib
Study Phase: Early Phase 1
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 10, 2025
Intervention Type: Drug
Study Drug: SRF388
Study Phase: Phase 1
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Lirilumab
Study Phase: Phase 1
A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Procedure, Other, Biological, Drug
Study Drugs: Atezolizumab, Glycosylated Recombinant IL-7
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Enrollment Status: Completed
Publish Date: April 27, 2022
Intervention Type: Biological
Study Drugs: CV-301, Atezolizumab
Study Phase: Phase 2
View 10 Less Clinical Trials

342 Total Publications

The Synergy of Percutaneous Coronary Intervention and Lifestyle Modification in Reducing Mortality and Blockage Prevention.
The Synergy of Percutaneous Coronary Intervention and Lifestyle Modification in Reducing Mortality and Blockage Prevention.
Journal: Cardiology in review
Published: December 08, 2025
View All 342 Publications
Similar Doctors
Distinguished in Paget's Disease of Bone
Dr. Meeta Sharma
Endocrinology
Distinguished in Paget's Disease of Bone
Dr. Meeta Sharma
Endocrinology

MedStar Health Endocrinology At MedStar Washington Hospital Center Physician Office Building North

106 Irving St NW Ste 3800, 
Washington, DC 
 (6.2 miles away)
202-877-2300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Meeta Sharma is an Endocrinologist in Washington, Washington, D.c.. Dr. Sharma is rated as an Advanced provider by MediFind in the treatment of Paget's Disease of Bone. Her top areas of expertise are Paget's Disease of Bone, Thyroid Storm, Hypothyroidism, and Type 2 Diabetes (T2D).

Kendall Moseley
Distinguished in Paget's Disease of Bone
Dr. Kendall Moseley
Endocrinology
Distinguished in Paget's Disease of Bone
Dr. Kendall Moseley
Endocrinology

Johns Hopkins Bayview Medical Center

4940 Eastern Avenue, Bayview Medical Offices, Level 1 (M), MSK, Bayview Medical Offices, Level 1 (M), MSK, 
Baltimore, MD 
 (36.0 miles away)
410-550-2663
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Kendall Moseley is the Clinical Director of the Division of Diabetes, Endocrinology & Metabolism, Medical Director of the Johns Hopkins Metabolic Bone & Osteoporosis Center and Co-Director of the Johns Hopkins Multidisciplinary Parathyroid Clinic. Dr. Moseley received her medical degree from Baylor College of Medicine in Houston, TX, followed by internal medicine residency training at the Johns Hopkins Hospital. Upon completion of her endocrinology fellowship at Johns Hopkins, she joined the faculty in the Division of Endocrinology, Diabetes & Metabolism of the Johns Hopkins University School of Medicine. Dr. Moseley has a dynamic clinical practice and collaborations within the institution that focus on metabolic bone diseases, osteoporosis, hyperparathyroidism, vitamin D deficiency, atypical fractures, and skeletal survivorship. She is actively engaged in NIH-funded clinical and translational research involving the relationship between type 2 diabetes, osteoporosis, and aging. She is additionally involved in research investigating mechanisms by which chronic disease states such as malignancy, HIV, hepatitis C, and cystic fibrosis impact bone quantity and quality. Clinically, she enjoys partnering with her patients and using their unique and often complex medical history to individually tailor effective diet, lifestyle, and treatment regimens to improve skeletal health. Dr. Moseley is rated as a Distinguished provider by MediFind in the treatment of Paget's Disease of Bone. Her top areas of expertise are Osteoporosis, Postmenopausal Osteoporosis, Paget's Disease of Bone, and Hyperparathyroidism.

Distinguished in Paget's Disease of Bone
Dr. Olufunmilayo Onobrakpeya
Endocrinology
Distinguished in Paget's Disease of Bone
Dr. Olufunmilayo Onobrakpeya
Endocrinology

Center For Diabetes And Endocrine

510 Upper Chesapeake Dr Ste 510, 
Bel Air, MD 
 (55.0 miles away)
443-643-3287
Languages Spoken:
English
See accepted insurances

Olufunmilayo Onobrakpeya is an Endocrinologist in Bel Air, Maryland. Dr. Onobrakpeya is rated as a Distinguished provider by MediFind in the treatment of Paget's Disease of Bone. Her top areas of expertise are Type 2 Diabetes (T2D), Diabetic Nephropathy, Thyroid Nodule, and Paget's Disease of Bone.

VIEW MORE PAGET'S DISEASE OF BONE DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jain's expertise for a condition
ConditionClose
  • Elite
  • Muscle Invasive Bladder Cancer
    Dr. Jain is
    Elite
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
    • Advanced
    • Hypercalcemia
      Dr. Jain is
      Advanced
      . Learn about Hypercalcemia.
      See more Hypercalcemia experts
    • Malnutrition
      Dr. Jain is
      Advanced
      . Learn about Malnutrition.
      See more Malnutrition experts
    • Maturity Onset Diabetes of the Young
      Dr. Jain is
      Advanced
      . Learn about Maturity Onset Diabetes of the Young.
      See more Maturity Onset Diabetes of the Young experts
    • Milk-Alkali Syndrome
      Dr. Jain is
      Advanced
      . Learn about Milk-Alkali Syndrome.
      See more Milk-Alkali Syndrome experts
    • Thyroid Storm
      Dr. Jain is
      Advanced
      . Learn about Thyroid Storm.
      See more Thyroid Storm experts
    • Type 1 Diabetes (T1D)
      Dr. Jain is
      Advanced
      . Learn about Type 1 Diabetes (T1D).
      See more Type 1 Diabetes (T1D) experts
    View All 7 Advanced Conditions
    • Experienced
    • Addison's Disease
      Dr. Jain is
      Experienced
      . Learn about Addison's Disease.
      See more Addison's Disease experts
    • Adrenal Insufficiency Pediatric
      Dr. Jain is
      Experienced
      . Learn about Adrenal Insufficiency Pediatric.
      See more Adrenal Insufficiency Pediatric experts
    • Anaplastic Thyroid Cancer
      Dr. Jain is
      Experienced
      . Learn about Anaplastic Thyroid Cancer.
      See more Anaplastic Thyroid Cancer experts
    • Colonoscopy
      Dr. Jain is
      Experienced
      . Learn about Colonoscopy.
      See more Colonoscopy experts
    • Diabetic Retinopathy
      Dr. Jain is
      Experienced
      . Learn about Diabetic Retinopathy.
      See more Diabetic Retinopathy experts
    • Endoscopy
      Dr. Jain is
      Experienced
      . Learn about Endoscopy.
      See more Endoscopy experts
    View All 48 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.